were 23 and 45 weeks respectively. Kaplan-Meier analysis of pre-treatment PWI revealed an 18 week reduction in median OS in patients with high tumor rCBV (p = 0.031). Changes in rCBV measures, especially load, correlated significantly with PFS and OS at both follow-up time-points. Patients with the greatest reduction in rCBV load by 8-weeks of therapy had a significantly increased median OS (30 weeks; p = 0.013). PWI may be of significant clinical utility in managing patients with rGBM, particularly those treated with anti-angiogenic agents such as bevacizumab. These findings need to be confirmed prospectively in larger studies.
Introduction
Bevacizumab is a humanized murine monoclonal antibody targeting vascular endothelial growth factor-A, and is approved for the treatment of recurrent glioblastoma multiforme (rGBM) based on initial reported response rates of 46 % [1] . Subsequent phase II studies have further demonstrated its efficacy in salvage therapy [2] . However, the progression-free survival (PFS) benefits of bevacizumab have not yet translated into improved overall survival (OS) in either the de novo or recurrent disease settings.
One concern is that MRI based assessment of bevacizumab response may be inaccurate and misleading. Pseudoresponse is well described when tumors are assessed by conventional MacDonald criteria due to decreasing tumor vessel permeability causing decreased contrast enhancement [2] . The RANO criteria were introduced to specifically account for this issue [3] . Newer imaging modalities not dependent on contrast-enhancement are also being investigated for determining outcome measures in GBM [4] .
Perfusion MRI, or perfusion-weighted imaging (PWI), rapidly obtains images to serially measure the movement of a tracer agent within a tissue of interest to give estimates of its haemodynamic properties. Reductions in PWI parameters such as permeability coefficients (e.g. K trans ) and cerebral blood volume (CBV) have been demonstrated with bevacizumab administration in both pre-clinical studies [5] [6] [7] and phase II clinical trials [8] . The ability of PWI to predict patient outcome remains uncertain, with mixed results being reported from the small number of studies investigating this relationship [9] [10] [11] .
This study retrospectively examined the prognostic value of PWI specifically in patients with rGBM treated with bevacizumab. In particular, the analysis included pretreatment scans and an "early" time-point scan undertaken after only 4 weeks of treatment.
Materials and methods

Patient selection and follow-up
Study participants were those patients recruited from The Royal Melbourne and Melbourne Private Hospitals for the CABARET randomized phase II clinical trial. Inclusion and exclusion criteria for the CABARET trial are listed in the supplementary material. Briefly, patients eligible for inclusion were those over 18 years old with a tissue diagnosis of GBM and disease recurrence on post-contrast MRI or confirmed histologically. Previous treatment with temozolomide and radiotherapy was mandatory. Patients were excluded if there was any evidence of recent intracerebral hemorrhage or an inability to undergo MRI. The study was conducted with institutional Human Research Ethics Committee approval.
Patient age, gender, and presenting functional status (KPS, Karnofsky Performance Status) were recorded at enrolment. Patients were followed prospectively to determine PFS and OS. PFS was defined as the time from randomization to clinical or radiographic progression. OS was determined by the time from randomization to death.
CABARET trial protocol
The CABARET trial is a randomized phase II multi-center study in patients with rGBM consisting of two parts. Part 1 randomized patients to bevacizumab alone or bevacizumab plus carboplatin. At disease progression, Part 2 randomized patients suitable for further therapy to either continuation of bevacizumab or discontinuation. Part 2 allowed patients to be treated with physicians' choice chemotherapy (carboplatin, temozolomide or etoposide).
MR imaging
MRI findings from pre-treatment scans, as well as the initial two follow-up scans during Part 1 of the trial were assessed for their ability to predict outcome. The first two followup scans were undertaken at 4-and 8-weeks following randomization as per trial protocol. While 8-week follow-up imaging is not unusual in studies of this kind as well as in clinical practice, the 4-week follow-up MRI represented a deliberate early time-point for radiographic assessment of treatment response, and was included to assess the value of early MRI in disease monitoring.
Patients underwent conventional MRI as part of the CABARET trial protocol. These studies normally also included PWI. The majority of investigations were undertaken on a 3-T scanner, with the remainder performed on 1.5-T machines. Although specific MRI protocols differed slightly between patients, they typically included T1 pre-and post-contrast administration, FLAIR, DWI and T2-weighted scans.
Dynamic susceptibility-weighted MRI was used for PWI whereby dynamic MR images were acquired during a bolus IV administration of contrast agent. A pragmatic attempt was made to acquire the data in accordance with previous recommendations [12] whilst keeping the total contrast agent dose within recommended limits, and obtaining acceptable slice coverage and image signalto-noise ratio. To reduce the effect of contrast leakage on CBV calculations, a 5 mL bolus of gadolinium contrast agent (Magnevist®, Bayer, Germany) was administered to the patient 5 min prior to the PWI acquisition at a rate of 1 mL/s followed by a 15 mL saline flush. For PWI, dynamic gradient-echo EPI images were then acquired every 1.5-3 s. After approximately 10 to 15 s of scanning, a 10 mL bolus of contrast agent was administered at a rate of 5 mL/s followed by a 30 mL saline flush. Due to the differences in MR system configurations the TR (1.2-3 s), TE (30-60 ms), in-plane resolution (1.2-3 mm), slice thickness (4-7 mm), slice number (14) (15) (16) (17) (18) (19) (20) and total acquisition times (70-100 s) were scanner dependent.
Post-acquisition imaging analysis
All imaging was transferred to an external computing station for post-acquisition processing. Using Analyze 10.0 (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN), tumor regions of interest (ROIs) were created from contrast-enhancing regions on T1-weighted sequences (T1 + C ROI) and hyperintense regions on FLAIR sequences (FLAIR ROI). Cystic cavities and necrotic cores were not included. A further ROI was created from T2-weighted normal-appearing white matter (NAWM) of the contralateral centrum semiovale.
PWI data were converted to maps proportional to contrast agent concentration to correct for blood vessel leakage in Matlab® 7.11 (Mathworks, Inc., MA, USA), and maps proportional to CBV were then created by numerical integration on a voxel by voxel basis [12] . The tumor and NAWM ROIs were then co-registered and re-sampled onto the CBV map frame of reference via a nine-parameter affine co-registration (MINC tools, Montreal Neurological Institute) of the T1 post-contrast, FLAIR and T2 scans to the first phase of the PWI images. Relative CBV (rCBV) maps were subsequently created, relative to the NAWM ROI, again using Matlab®. Tumor voxel rCBV histograms were then created for the T1 + C and FLAIR ROIs.
Interval and serial imaging characteristics
For each patient, T1 contrast-enhancing and FLAIRhyperintense tumor volumes (cm 3 ) were calculated for the three (pre-treatment, and 4-and 8-week follow-up) imaging time-points by integrating the number of voxels within each corresponding ROI by the voxel volumes within Matlab®. Traditional tumor rCBV histogram statistics (mean, median, mode and maximum) were obtained from the histogram data of each tumor ROI. Additionally, a novel rCBV measurement was calculated to give a volumetric indicator of total tumor perfusion load. This was achieved by determining the numerical integral of the voxel rCBV histogram for a given tumor ROI (rCBV load ).
Values of traditional tumor rCBV histogram statistics, and rCBV load , for each imaging time-point were then compared to determine serial changes in these characteristics, expressed as a percentage. Definitions of volumetric progression (>40 % increase in volume) and response (>65 % reduction in volume) were applied to changes in T1 + C and FLAIR tumor volumes, as well as the volumetric perfusion measurement rCBV load , to determine rates of radiographic progression and response [13, 14] .
Statistical analysis
Statistical analysis was performed using Prism 5 for Mac OS X (GraphPad Software, Inc., San Diego). Correlations between rCBV measures and outcome were investigated using the Spearman correlation test. Patients surviving at time of analysis were censored at that date. Patients were also dichotomized to low and high rCBV mean , rCBV median , rCBV mode , rCBV max , and rCBV load groups based on the median value of each of the five parameters, at each imaging timepoint log-rank tests were then used to compare the Kaplan-Meier survival curves of these groups. The same analyses were applied to the percentage change in rCBV values at each follow-up imaging time-point. Statistical significance was considered to be p < 0.05 for all tests.
Results
Patient demographics and outcome
A total of 122 patients were enrolled in the CABARET trial, including 15 from our institutions between April 2011 and Feb 2012. For these 15 patients, the mean patient age was 49 years, with more males recruited (n = 9). Tumors were most commonly located in the frontal lobe (n = 5). The majority of patients (n = 12) exhibited good functional status at enrolment (KPS score 80-100), with three patients displaying moderate functional status (KPS score 50-70).
At the time of analysis only one patient was alive and was censored for outcome analyses. One patient underwent further resection prior to commencement of treatment to confirm recurrence rather than radiation necrosis. This patient was excluded from response analyses as any change in tumor volume would be the result of treatment plus surgery. One patient discontinued treatment after 4 months due to acute renal impairment potentially caused by bevacizumab. Outcome data from this patient has been included. PFS and OS data was available for all patients. Median PFS and OS was 23 weeks [standard deviation (SD) ±24 weeks] and 45 weeks (SD ±22 weeks) respectively.
Pre-treatment MRI
All patients had conventional pre-treatment MRI available for analysis. Nine out of 15 MR scans were performed on the same 3 T machine. Scans were undertaken on average 24 days (SD ±23 days) prior to commencing treatment. The average contrast-enhancing tumor volume was 27 cm 3 (SD ±23 cm 3 ), while the average FLAIR hyperintense volume was 137 cm 3 (SD ±56 cm 3 ). Pre-treatment MR imaging also included PWI for 13 patients. Based on Spearman analysis, no rCBV measure was found to significantly correlate with PFS or OS. However, Kaplan-Meier analysis demonstrated a significant difference in OS curves between patients with low vs. high rCBV median (Fig. 1a) . Median survival was reduced by 18 weeks in patients with high rCBVs (53 vs. 35 weeks).
4-week follow-up MRI
All patients had the initial follow-up MRI available for analysis, undertaken on average 26 days (SD ±3 days) following commencing treatment. 14 out of 15 4-week MR scans were performed on the same 3 T machine. The average contrast-enhancing tumor volume was 10 cm 3 (SD ±10 cm 3 ), while the average FLAIR hyperintense volume was 70 cm 3 (SD ±27 cm 3 ). Spearman analysis of PWI revealed significant negative correlations between tumor rCBVs and both PFS and OS (Table 1) . Kaplan-Meier analysis demonstrated a significant reduction in PFS in patients with large rCB-V load (median PFS 23 vs. 15 weeks; Fig. 1b ). Significant reductions in OS were demonstrated in patients with high tumor rCBVs (Fig. 1c, d ). High rCBV median and rCBV max decreased median OS by 14 (52 vs. 38) and 21 (52 vs. 31) weeks respectively.
8-week follow-up MRI
One patient had clinical and radiographic evidence of disease progression after 4-weeks follow-up and was excluded from analysis of the 8-week follow-up MRI. The remaining 14 patients all had MRI (including PWI) available, which was undertaken on average 55 days (SD ±7 days) following commencing treatment, and 13/14 were perfomed on the 3 T machine. The average contrast-enhancing tumor volume was 6 cm 3 (SD ±9 cm 3 ), while the average FLAIR hyperintense volume was 60 cm 3 (SD ±27 cm 3 ). Spearman analysis of PWI revealed significant negative correlations between tumor rCBVs and both PFS and OS (Table 1) . Kaplan-Meier analysis demonstrated a significant reduction in PFS in patients with large rCBV load (median PFS 32 vs. 16 weeks; Fig. 2a ). Significant reductions in OS were also demonstrated in patients with high tumor rCBVs based on T1 + C ROIs (Fig. 2b-d) . Median OS was reduced by 13 (54 vs. 41) weeks in patients with high rCBV mean , and by 16 (54 vs. 38) weeks in patients with high rCBV mode and large rCBV load (Fig. 2b-d) .
Predicting response to bevacizumab based on volumetric criteria and PWI
Comparing pre-treatment to follow-up MRIs gave volumetric response rates of 50 % at 4 weeks and 69 % at 8 weeks using conventional T1 post-contrast imaging. FLAIR imaging gave lower response rates (14 and 35 %), whilst including changes in perfusion through rCBV load returned higher response rates (45 and 91 %). Volumetric progression was demonstrated only on conventional T1 post-contrast imaging for one patient, giving a rate of progression of 7 %.
Comparisons between outcome and changes in rCBV at 8 weeks, based on T1 + C ROIs are shown in Fig. 3 and Table 2 . Spearman and Kaplan-Meier analyses both demonstrated that patients with the greatest reductions in rCBV had improved PFS and OS. Median OS was increased by 30 weeks in patients with the greatest reduction in rCBV load at 8 weeks compared to pre-treatment imaging (Fig. 3b) . No significant correlations were seen at the 4-week MRI or using changes in FLAIR ROI rCBVs.
Discussion
Imaging-based assessment of response to therapy in GBM has traditionally involved two-dimensional measurements of contrast-enhancing tumor regions as recommended by MacDonald and colleagues in 1990 [15] . Limitations with this criteria became increasingly apparent as therapyinduced pseudo-progression and pseudo-response gained recognition. This prompted an updated response criteria (RANO) to be published in 2010, including non-enhancing regions of tumor in the imaging-based assessment of response [3] . As volumetric analysis and advanced imaging techniques such as PWI become more accessible it is likely that they will become incorporated into future revisions [14] . The current study investigated the ability of PWI to predict outcome in patients with rGBM treated with bevacizumab. Pre-treatment as well as early follow-up imaging were examined for associations with PFS and OS. Changes in perfusion imaging over time were also analyzed for links with outcome.
Fifteen patients were recruited for the CABARET trial from our institutions, and all were included in this analysis. Follow-up for all patients was complete and median PFS and OS were 23 and 45 weeks respectively. Compared with historical data, this cohort did far better than expected for patients with rGBM (PFS ~10 weeks; OS ~30 weeks [16] ). However, their outcomes are comparable to results from other phase II trials of bevacizumab therapy in rGBM patients [17] [18] [19] [20] [21] .
In this study, patients with higher median rCBV within FLAIR hyperintense tumor volumes on pre-treatment MRI were found to have significantly reduced OS compared to those with lower values (53 vs. 35 week; Fig. 1a ). This may simply reflect the poorer prognosis seen in patients with more vascular tumors, though it also suggests that these patients may be less likely to benefit from anti-angiogenic therapies such as bevacizumab. Perfusion MRI at the time of GBM recurrence may therefore be useful in selecting which patients should be considered for anti-angiogenic therapy.
Following the commencement of anti-angiogenic agents, PWI analysis of the contrast-enhancing tumor regions, rather than FLAIR hyperintense regions, appears to become more important in monitoring response and predicting outcome. After 4 weeks of therapy with bevacizumab, median rCBV on FLAIR ROIs correlated with both PFS and OS, but stronger and more significant correlations with OS were seen with T1 + C ROI rCBV histogram statistics. By 8 weeks of therapy, all correlations were lost with FLAIR ROI rCBV histogram statistics, but became stronger with T1 + C ROIs. The reason for this shift in significance from FLAIR to T1 + C during treatment is uncertain, but may relate to a greater sensitivity of contrast-enhancing tumor to the effects of anti-angiogenic agents. Changes in tumor volume with treatment were also greatest on T1 post-contrast imaging.
Follow-up PWI as early as 4 weeks was able to predict outcome in patients receiving bevacizumab. At this imaging time point, patients with high rCBVs demonstrated reductions in OS between 14 and 21 weeks compared to patients with low values. This predictive value persisted and strengthened by the 8-week follow-up MRI. Again, these findings may reflect the poorer prognosis associated with more highly vascular tumors, but it is interesting to note that also patients with the smallest reductions, or any increase, in tumor rCBV measures following commencement of treatment were demonstrated to have worse PFS and OS.
The strongest and most significant correlations between these PWI changes with bevacizumab therapy and outcome were seen with rCBV load . This novel rCBV measurement was developed to estimate the total volume of blood vessels within a given tumor. Unlike histogram statistics, which do not vary with tumor size, rCBV load takes into account the entire mass of abnormal tumor vasculature that is responding to treatment. Increases in rCBV load at the 4-and 8-week follow-up MRIs were associated with both poorer PFS and OS.
Imaging response rates were also assessed using true volumetric analysis. Using RECIST criteria, response rates of 50 and 69 % were seen at 4-and 8-week followup respectively. Response rates from other phase II trials of bevacizumab for rGBM using MacDonald imaging criteria range from 23 to 57 % following long-term follow-up [10, [17] [18] [19] [20] [21] . The increased response rate seen in the current study may relate to a number of factors including differences in treatment regimens and patient populations. However, one phase II study of bevacizumab in rGBM patients has directly compared MacDonald criteria to volumetric analysis of imaging response at early timepoints (3 and 21 days), and also reported higher response rates with the volumetric analysis [8] . This suggests that volumetric analysis may be a more sensitive way of monitoring GBM response to therapy.
A shortcoming of this study was that 9 of 15 subjects had baseline scans on a 1.5 T scanner and underwent further MRI studies on a 3 T scanner. This was a result of all baseline scans for this clinical trial being taken from the subjects standard clinical MRI exams which were spread over our institution's three MRI scanners and some external Radiology sites. For the perfusion scanning the main effect of this would have been lower image resolution and thicker slices at 1.5 T. The effect on rCBV measures would have been minimal as the main difference would have been the differing T1 contamination of the rCBV values. This was carefully corrected for as previously recommended. In a recent study, 1.5 and 3 T rCBV values were found to be highly correlated (ICC = 0.92 [95 % CI 0.85-0.97]) [22] .
Although the CABARET trial is a large, well designed, multi-center, prospective clinical trial, this report represents an essentially retrospective ad hoc analysis of the data obtained from one of its recruiting centers. This leads to a number of inherent limitations including small sample size.
The lack of PWI in the CABARET protocol also meant that not all patients in the current study underwent pre-treatment PWI (13 of 15) . Despite these problems, highly significant correlations and differences in outcome were still observable.
Conclusion
Findings from this study suggest that PWI may be of significant clinical utility in managing patients with rGBM treated with anti-angiogenic agents such as bevacizumab. We have demonstrated that pre-treatment PWI may be able to help in selecting which patients are likely to benefit most from bevacizumab. We have also shown that early follow-up imaging, even at 4 weeks, may help in identifying which patients are less likely to gain from continued use of anti-angiogenic agents and for whom other treatments should be sought. Monitoring changes in the entire tumor blood vessel volume, with rCBV load , appears to be the most useful way to identify such patients. These findings will necessarily need to be confirmed in larger studies.
